Skip to Content

ZTlido Approval History

  • FDA approved: Yes (First approved February 28th, 2018)
  • Brand name: ZTlido
  • Generic name: lidocaine
  • Dosage form: Patch
  • Previous name: Ztilido
  • Company: Scilex Pharmaceuticals, Inc.
  • Treatment for: Postherpetic Neuralgia

ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with postherpetic neuralgia.

Development History and FDA Approval Process for ZTlido

Feb 28, 2018Approval Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain
Sep 12, 2017FDA Acknowledges Receipt of Sorrento Therapeutics Inc, NDA for ZTlido
Aug 29, 2017Sorrento Therapeutics, Inc. Submits NDA For ZTlido Next-Generation Lidocaine Patch
Sep 16, 2015FDA Accepts Scilex Pharmaceuticals' NDA Filing for ZTlido
May 15, 2014Scilex Pharmaceuticals Initiates Pivotal Pharmacokinetic Study for Ztilido
Mar 24, 2014Scilex Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztilido

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.